Iovance Biotherapeutics (IOVA)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Iovance Biotherapeutics (IOVA)
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Key Insights
Critical company metrics and information
Share Price
$8.72Market Cap
$2.66 BillionTotal Outstanding Shares
304.78 Million SharesTotal Employees
557Dividend
No dividendIPO Date
October 15, 2010SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.iovance.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities | $-48.80 Million |
Net Cash Flow From Operating Activities | $-58.97 Million |
Net Cash Flow, Continuing | $-65.82 Million |
Net Cash Flow From Investing Activities, Continuing | $-48.80 Million |
Exchange Gains/Losses | $1.25 Million |
Net Cash Flow | $-64.57 Million |
Net Cash Flow From Operating Activities, Continuing | $-58.97 Million |
Net Cash Flow From Financing Activities | $41.95 Million |
Net Cash Flow From Financing Activities, Continuing | $41.95 Million |
Income Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss Attributable To Parent | $-83.54 Million |
Diluted Earnings Per Share | $0.28 |
Costs And Expenses | $147.62 Million |
Income/Loss From Continuing Operations After Tax | $-83.54 Million |
Gross Profit | $18.73 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-83.54 Million |
Revenues | $58.55 Million |
Operating Income/Loss | $-89.07 Million |
Income Tax Expense/Benefit | $-1.52 Million |
Other Operating Expenses | $39.55 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Basic Average Shares | $303269.00 |
Basic Earnings Per Share | $0.28 |
Benefits Costs and Expenses | $143.62 Million |
Operating Expenses | $107.80 Million |
Income Tax Expense/Benefit, Deferred | $-1.52 Million |
Research and Development | $68.25 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Net Income/Loss | $-83.54 Million |
Diluted Average Shares | $303269.00 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Cost Of Revenue | $39.82 Million |
Income/Loss From Continuing Operations Before Tax | $-85.06 Million |
Balance Sheet
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Noncurrent Liabilities | $99.60 Million |
Fixed Assets | $112.52 Million |
Current Liabilities | $118.06 Million |
Liabilities And Equity | $991.12 Million |
Assets | $991.12 Million |
Noncurrent Assets | $492.54 Million |
Other Current Assets | $460.00 Million |
Other Current Liabilities | $86.37 Million |
Accounts Payable | $31.69 Million |
Equity Attributable To Parent | $773.46 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Current Assets | $498.58 Million |
Inventory | $38.58 Million |
Other Non-current Assets | $380.02 Million |
Liabilities | $217.66 Million |
Equity | $773.46 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.